335 related articles for article (PubMed ID: 33763494)
21. The Rise and Fall of Hydroxychloroquine for the Treatment and Prevention of COVID-19.
Lee Z; Rayner CR; Forrest JI; Nachega JB; Senchaudhuri E; Mills EJ
Am J Trop Med Hyg; 2021 Jan; 104(1):35-38. PubMed ID: 33236703
[TBL] [Abstract][Full Text] [Related]
22. Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review.
Rodrigo C; Fernando SD; Rajapakse S
Clin Microbiol Infect; 2020 Aug; 26(8):979-987. PubMed ID: 32470568
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
[TBL] [Abstract][Full Text] [Related]
24. Safety of hydroxychloroquine for treatment or prevention of SARS-CoV-2 infection: A rapid systematic review and meta-analysis of randomized clinical trials.
Maraolo AE; Grossi A
Immun Inflamm Dis; 2021 Mar; 9(1):31-36. PubMed ID: 33244901
[TBL] [Abstract][Full Text] [Related]
25. RETRACTED: Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study.
Abd-Elsalam S; Esmail ES; Khalaf M; Abdo EF; Medhat MA; Abd El Ghafar MS; Ahmed OA; Soliman S; Serangawy GN; Alboraie M
Am J Trop Med Hyg; 2020 Oct; 103(4):1635-1639. PubMed ID: 32828135
[TBL] [Abstract][Full Text] [Related]
26. Hydroxychloroquine/Chloroquine as Therapeutics for COVID-19: Truth under the Mystery.
Chen Y; Li MX; Lu GD; Shen HM; Zhou J
Int J Biol Sci; 2021; 17(6):1538-1546. PubMed ID: 33907517
[TBL] [Abstract][Full Text] [Related]
27. "H" is not for hydroxychloroquine-"H" is for heparin: lack of efficacy of hydroxychloroquine and the role of heparin in COVID-19-preliminary data of a prospective and interventional study from Brazil.
de Oliveira Costa R; Nascimento JS; Reichert CO; da Costa APA; Dos Santos MAP; Soares AM; Tomé CEM; Hayden RL; Dos Santos CW; Barreiro B; El-Khatib AAB; de Pádua Covas Lage LA; Pereira J; Benetti MM
BMC Infect Dis; 2022 Feb; 22(1):120. PubMed ID: 35120461
[TBL] [Abstract][Full Text] [Related]
28. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.
Maisonnasse P; Guedj J; Contreras V; Behillil S; Solas C; Marlin R; Naninck T; Pizzorno A; Lemaitre J; Gonçalves A; Kahlaoui N; Terrier O; Fang RHT; Enouf V; Dereuddre-Bosquet N; Brisebarre A; Touret F; Chapon C; Hoen B; Lina B; Calatrava MR; van der Werf S; de Lamballerie X; Le Grand R
Nature; 2020 Sep; 585(7826):584-587. PubMed ID: 32698191
[TBL] [Abstract][Full Text] [Related]
29. Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering.
Di Castelnuovo A; Gialluisi A; Antinori A; Berselli N; Blandi L; Bonaccio M; Bruno R; Cauda R; Costanzo S; Guaraldi G; Menicanti L; Mennuni M; My I; Parruti G; Patti G; Perlini S; Santilli F; Signorelli C; Stefanini G; Vergori A; Ageno W; Agodi A; Agostoni P; Aiello L; Al Moghazi S; Arboretti R; Aucella F; Barbieri G; Barchitta M; Bonfanti P; Cacciatore F; Caiano L; Cannata F; Carrozzi L; Cascio A; Castiglione G; Ciccullo A; Cingolani A; Cipollone F; Colomba C; Colombo C; Crisetti A; Crosta F; Danzi GB; D'Ardes D; de Gaetano Donati K; Di Gennaro F; Di Tano G; D'Offizi G; Fusco FM; Gaudiosi C; Gentile I; Gianfagna F; Giuliano G; Graziani E; Guarnieri G; Langella V; Larizza G; Leone A; Maccagni G; Magni F; Maitan S; Mancarella S; Manuele R; Mapelli M; Maragna R; Marcucci R; Maresca G; Marongiu S; Marotta C; Marra L; Mastroianni F; Mengozzi A; Meschiari M; Milic J; Minutolo F; Mussinelli R; Mussini C; Musso M; Odone A; Olivieri M; Palimodde A; Pasi E; Pesavento R; Petri F; Pivato CA; Poletti V; Ravaglia C; Righetti G; Rognoni A; Rossato M; Rossi I; Rossi M; Sabena A; Salinaro F; Sangiovanni V; Sanrocco C; Schiano Moriello N; Scorzolini L; Sgariglia R; Simeone PG; Spinicci M; Tamburrini E; Torti C; Trecarichi EM; Vettor R; Vianello A; Vinceti M; Virdis A; De Caterina R; Iacoviello L
J Healthc Eng; 2021; 2021():5556207. PubMed ID: 34336157
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting.
Mokhtari M; Mohraz M; Gouya MM; Namdari Tabar H; Tabrizi JS; Tayeri K; Aghamohamadi S; Rajabpoor Z; Karami M; Raeisi A; Rahmani H; Khalili H
Int Immunopharmacol; 2021 Jul; 96():107636. PubMed ID: 34015598
[TBL] [Abstract][Full Text] [Related]
31. Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine.
Bonam SR; Muller S; Bayry J; Klionsky DJ
Autophagy; 2020 Dec; 16(12):2260-2266. PubMed ID: 32522067
[TBL] [Abstract][Full Text] [Related]
32. The Role of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis.
Shamshirian A; Hessami A; Heydari K; Navaei RA; Ebrahimzadeh MA; Yip GW; Ghasemian R; Sedaghat M; Baradaran H; Yazdi SM; Aboufazeli E; Jafarpour H; Dadgostar E; Tirandazi B; Sadeghnezhad R; Karimifar K; Eftekhari A; Shamshirian D
Ann Acad Med Singap; 2020 Oct; 49(10):789-800. PubMed ID: 33283842
[TBL] [Abstract][Full Text] [Related]
33. Pharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans.
Gerlovin H; Posner DC; Ho YL; Rentsch CT; Tate JP; King JT; Kurgansky KE; Danciu I; Costa L; Linares FA; Goethert ID; Jacobson DA; Freiberg MS; Begoli E; Muralidhar S; Ramoni RB; Tourassi G; Gaziano JM; Justice AC; Gagnon DR; Cho K
Am J Epidemiol; 2021 Nov; 190(11):2405-2419. PubMed ID: 34165150
[TBL] [Abstract][Full Text] [Related]
34. Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients That Should Be Ramped Up Immediately as Key to the Pandemic Crisis.
Risch HA
Am J Epidemiol; 2020 Nov; 189(11):1218-1226. PubMed ID: 32458969
[TBL] [Abstract][Full Text] [Related]
35. Many trials of hydroxychloroquine for SARS-CoV-2 were redundant and potentially unethical: an analysis of the NIH clinical trials registry.
Yogendrakumar V; Dewar B; McGuinty M; Dowlatshahi D; Dyason C; Kwok ES; Ramsay T; Lund H; Shamy M
J Clin Epidemiol; 2022 Mar; 143():73-80. PubMed ID: 34780978
[TBL] [Abstract][Full Text] [Related]
36. 4-Aminoquinoline compounds from the Spanish flu to COVID-19.
Bazotte RB; Hirabara SM; Serdan TAD; Gritte RB; Souza-Siqueira T; Gorjao R; Masi LN; Antunes MM; Cruzat V; Pithon-Curi TC; Curi R
Biomed Pharmacother; 2021 Mar; 135():111138. PubMed ID: 33360781
[TBL] [Abstract][Full Text] [Related]
37. Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial.
Davoodi L; Abedi SM; Salehifar E; Alizadeh-Navaei R; Rouhanizadeh H; Khorasani G; Hosseinimehr SJ
Int J Clin Pract; 2020 Nov; 74(11):e13600. PubMed ID: 32603531
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the prophylactic effect of hydroxychloroquine on people in close-contact with patients with COVID-19.
Shabani M; Totonchi M; Rezaeimirghaed O; Gachkar L; Hajiesmaeili M; Khoshkar A; Amirdosara M; Saffaei A; Shokouhi S; Mardani M; Alavi Darazam I; Karami A; Sharifi M; Zaman M; Abedheydari E; Sahraei Z
Pulm Pharmacol Ther; 2021 Oct; 70():102069. PubMed ID: 34389507
[TBL] [Abstract][Full Text] [Related]
39. Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study.
Jung SY; Kim MS; Kim MC; Choi SH; Chung JW; Choi ST
Clin Microbiol Infect; 2021 Apr; 27(4):611-617. PubMed ID: 33316402
[TBL] [Abstract][Full Text] [Related]
40. Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine.
Choudhury M; Dhanabalan AK; Goswami N
J Cell Biochem; 2022 Feb; 123(2):347-358. PubMed ID: 34741481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
